Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the "14th Five-Year Plan" period, discussing innovative technologies and products that can sustain the industry's vitality [1]. Group 2: Organizers and Highlights - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. - Key highlights include forums on biomanufacturing trends, youth innovation sharing, project roadshows, and participation from leading enterprises, top universities, and investment institutions [4]. Group 3: Agenda and Special Activities - The first day features a closed-door high-level seminar focusing on biomanufacturing development trends and growth points, inviting 30 industry leaders and experts [7]. - The second and third days will include a macro forum on biomanufacturing, specialized sub-forums on green chemicals, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. Group 4: Focus Areas in Sub-Forums - Sub-forum topics include the development of bio-based chemicals, green manufacturing technologies for fine chemicals, and the use of non-food raw materials for high-value product development [11]. - AI applications in biomanufacturing will also be discussed, including the use of AI for enzyme discovery and industrial fermentation process control [11].

Core Insights - The article discusses the upgrade of Tushen Zhihuo's protein design platform to ProteinNova, which now features AI-driven full-process protein design capabilities [1][5] - The integration of dry and wet lab processes allows for a closed-loop system in AI protein design, enhancing the efficiency of scientific research and product development [2][5] Group 1: AI-Driven Protein Design - The upgraded platform showcases a complete closed-loop process from AI-generated design to experimental validation, emphasizing the importance of real-world testing in scientific research [2] - The platform's capabilities include task management, data tracking, and feedback integration, enabling users to create personalized iterative tasks for rapid prototype validation [2][5] Group 2: Optimization of Decision-Making - The system's reasoning process has been streamlined to enhance clarity and user experience, allowing users to quickly grasp core insights without being distracted by unnecessary steps [3] - A complete logical chain is maintained for users who wish to delve deeper into the AI's reasoning, ensuring transparency while keeping the process efficient [3] Group 3: Reporting Enhancements - The introduction of structured report templates allows AI to extract key information such as design logic and improvement suggestions, improving report readability and usability [4] - The language of the reports has been optimized to balance scientific rigor with accessibility for researchers [4] Group 4: Future Implications - The launch of the dry-wet iteration system marks a significant advancement in AI's role in scientific research, enabling rapid feedback and self-optimization [5] - The platform aims to support a wider range of disciplines and experimental types, moving towards the realization of "automated science" as a foundational tool for research teams [5] Group 5: Company Background - Tushen Zhihuo focuses on accelerating scientific breakthroughs and product innovation through super-intelligent platforms, significantly reducing the cycle time for new product design [6] - The core team comprises experts from prestigious institutions, bringing extensive experience in AI research and commercialization [6]

Group 1 - The "Tian Kai High Education Science and Technology Innovation Park" in Tianjin has launched the "Tian Kai Tunbo Park" with a total investment fund of 2 billion yuan, focusing on the health industry sectors such as medical testing, medical devices, synthetic biology, and health rehabilitation [1] - The fund has already secured partnerships with 6 sub-funds and has a total of 26 projects in reserve, aiming to promote the upgrade of traditional industries and the growth of emerging industries through a "project reserve + industry cultivation" model [1] - The park covers an area of 10.9 square kilometers and aims to create a high ground for the health industry, injecting new momentum into the coordinated development of the Beijing-Tianjin-Hebei region [1] Group 2 - Tianjin Jinghai has introduced the "Tian Kai Tunbo Park 10 Policies" to optimize supply in key areas such as resource sharing, achievement transformation, carrier utilization, enterprise development, and talent introduction [2] - The park has established the first national "patent pool" for traditional Chinese medicine and the first national key laboratory for traditional Chinese medicine, with 33 patents already transformed [2] - The park aims to build a comprehensive four-dimensional collaborative model of medicine, education, research, and production over the next five years, leveraging both traditional Chinese and Western medicine advantages [2]

Core Viewpoint - The Tian Kai Gaokao Science and Technology Innovation Park in Tunbo is set to become a significant hub for the health industry, focusing on the integration of medical, educational, research, and industrial resources to drive innovation and development in the Beijing-Tianjin-Hebei region [2][3]. Group 1: Policy and Support - The park has introduced a set of 10 policies aimed at optimizing resource sharing, results transformation, and talent introduction, which will accelerate the cultivation of new productive forces in the health industry [2]. - A total of 2 billion yuan innovation industry development fund has been established to support project upgrades, along with 100 million yuan in special funds for technological innovation [2][7]. Group 2: Infrastructure and Ecosystem - The Tian Kai Gaokao Park has developed 93,000 square meters of innovation space and is constructing an additional 82,000 square meters of incubation space to support enterprise growth [4]. - The park aims to create a full lifecycle service system for the transformation of technological innovations by attracting various incubators and financial service channels [4]. Group 3: Collaborative Development - The park will focus on nine national-level innovation platforms in the health sector, collaborating with several universities and research institutions to foster a comprehensive innovation ecosystem [3]. - The park has established a knowledge property service system that covers the entire chain from research and development to evaluation and transformation, identifying 50 high-value patents for further development [6]. Group 4: Investment and Future Plans - The "Tunbo Innovation Industry Development Fund" is led by Huahai Guotou and aims to invest in sectors such as medical testing, medical devices, and rehabilitation within the health industry [7]. - The park plans to leverage its historical opportunities to enhance the innovation capabilities of the health industry over the next five years by integrating medical, educational, research, and industrial resources [7].

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the 14th Five-Year Plan and identify innovative technologies and products that will sustain the industry's vitality [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - The conference will feature forums and closed-door activities to gain insights into the development trends of biomanufacturing during the 14th Five-Year Plan, exploring new products, technologies, and collaborations [4]. - There will be over 100 financing project roadshows to discover new cooperation opportunities [4]. - Key industry leaders, top universities, and capital from various sectors will gather to discuss advancements in biomanufacturing [4]. Group 4: Agenda and Special Activities - The first day will include a closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts for in-depth discussions [7]. - The second and third days will feature a macro forum on biomanufacturing, covering the development trends and progress of policies related to the industry [10]. Group 5: Specialized Forums - Specialized forums will cover topics such as green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - The forums will address various key topics, including the development of bio-based chemicals, green manufacturing technologies, and the application of AI in biomanufacturing processes [11].

蔗糖是一种常见的大宗药用辅料。在当前全球普遍关注肥胖和糖尿病等代谢性疾病的背景下，医药界开 始寻找安全的代糖产品。阿洛酮糖被业界视为继蔗糖、果糖之后，最可能实现规模化应用的天然健康 糖。合成生物技术让阿洛酮糖的低价量产成为可能，据李响介绍，这也促成了微元合成和国药集团的一 次合作落地。 上述案例是当下医药大健康行业企业"牵手"合成生物公司的一个缩影。近年来，无论是在创新药及创新 疗法、原料药及中间体制造等创新药研发领域还是在前述如阿洛酮糖等"三新"（新食品原料、食品添加 剂新品种、食品相关产品新品种）健康食品领域，我国合成生物技术均涌现出一批创新成果。 2025年上半年，合成生物及生物制造领域投资热情不减，其中市场主力为地方国资。 八包板蓝根颗粒把一名成年男性"送进"ICU。后经诊断，由于短时间内摄入过多糖分，这名有糖尿病和 高血压病史的男性被诱发糖尿病酮症酸中毒。 19日，在2025年"活力中国调研行"期间，微元合成生物技术（北京）有限公司（下称"微元合成"）首席 运营官李响分享了上述这个在国内真实发生的事件。 多地"真金白银"扶持合成生物创新企业 目前，北京、上海等地相继推出了支持合成生物产业发展的一揽子 ...

资本事件 | 三井化学 【SynBioCon】 获 悉，6月19日， 三井化学 宣布通 过321FORCE™全球 创新基金（321FORCE）投资了一家总部位于英国伦敦 的 细胞培养替代脂肪 初创Hoxton Farms 。 而就在 今年3月， Hoxton Farms正展开 与 日本住友公司 Sumitomo Corporation达成战略合作，共同推动培育脂肪 Hoxton Fat在 日本及亚太市场 的 应用。 在应用方面 ，双 方将Hoxton Fat整合到多种食品中， 从汤和酱汁到咸味糕点和加工肉类 。 资质方面 ，公司将与日本监管机构合作，在日本细胞农业协会 （JACA）的协助下获得相关的食品安全 批准。 市场方面，亚洲肉类需求增长对健康与食品安全的影响 。 随着收入增长、城市化进程加快及人口增长，亚洲消费者的饮食结构正在发生变化，高热量、高饱和脂肪的食品摄入量不断上升，肥胖问题日益严重。亚太 地区超过40%的成年人超重或肥胖，因肥胖及相关疾病导致的医疗支出占比高达12%。 与此同时， 亚洲的肉类需求预计到2050年将增长78% 。供应链不稳定、气候变化及疾病传播进一步加剧了食品安全危机。在这一背景 ...

Core Viewpoint - The article emphasizes the importance of biomanufacturing as a key focus for enhancing economic competitiveness in various countries, including China, which is advancing its manufacturing capabilities through initiatives like green manufacturing and intelligent manufacturing [1]. Group 1: Event Overview - The Fourth Synthetic Biology and Green Biomanufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on the integration of AI and biomanufacturing [1]. - The conference aims to explore the development trends of the biomanufacturing industry during the "14th Five-Year Plan" period, discussing innovative technologies and products that can sustain the industry's vitality [1]. Group 2: Organizing Institutions - The conference is organized by Ningbo Detaizhong Research Information Technology Co., Ltd. (DT New Materials) and co-organized by Ningbo Meisai Biological Engineering Co., Ltd. [2]. Group 3: Highlights of the Conference - The conference will feature forums and closed-door activities to gain insights into the development trends of biomanufacturing during the "14th Five-Year Plan" [4]. - There will be over 100 financing project roadshows to discover new cooperation opportunities [4]. - Key industry leaders, top universities, and capital from various sectors will gather to discuss and share insights [4]. Group 4: Agenda and Special Activities - The first day will include a closed-door seminar focusing on the development trends and growth points of biomanufacturing, inviting 30 industry leaders and experts [7]. - The second and third days will feature a macro forum on biomanufacturing, discussing the overall trends and progress in the industry [10]. Group 5: Specialized Forums - Specialized forums will cover topics such as green chemicals and new materials, AI in biomanufacturing, future food and agriculture, and beauty raw materials [11]. - The forums will address various key topics, including the development of bio-based chemicals, green manufacturing technologies, and the application of AI in biomanufacturing processes [11]. Group 6: Technology and Innovation - The conference will showcase technological achievements and innovations in the field of biomanufacturing, inviting participation from research institutions and enterprises [10]. - There will be a focus on discovering potential teams and technologies in biomanufacturing, with over 30 presentations planned to facilitate efficient communication and collaboration [10].

近年来，生物制造已作为多数国家提升经济竞争力的着力点，也是我国继绿色制造、智能制造后，推进制造强国建设的又一重要抓手。同时，各地政府 地区通过结合自身优势力争实现合成生物"研发－转化－产业—集群"协同发展，发挥新质生产力 作用。 8月20-22日 将于 浙江·宁波 举 办 第四届合成生物与绿色生物制造大会 (简称： SynBioCon 2 025 ) 。大会 聚焦" 1+4 " ： AI+生 物智造 这一大热门赛道； 绿色化工与新材料、 未来食品、未来农业和美妆原料四大应用领域 ，邀请国 际领先企业、代表性产业化专家、政府、园 区、资本、协会和联盟等各方共探 "十五五"生物制造产业发展趋势 ； 哪些革新技术和产品将给生物制造产业带来持续的生命力 ； 并致力于 促进科技 成果转移转化 、 产品 规模 化与人才挖掘 。 一、组织机构 主办单位： 宁波德泰中研信息科技有限公司（ DT 新材料） 协办 单位： 宁波酶赛生物工程有限公司 二、大会亮点 三、大会日程 亮点一 ： 大会论坛、闭门活动洞察"十五五"生物制造发展趋势！探索新产品、新技术、新落地、 新合作！ 亮点二： 青年创新技术与价值分享、人才对接与合作！ 亮 ...

Core Viewpoint - The synthetic biology industry is rapidly developing in China, supported by government policies, and is expected to become a new golden track for investment opportunities [1][2]. Industry Overview - Synthetic biology is recognized as one of the most transformative technologies in the life sciences of the 21st century, with various regions in China, including Shenzhen, prioritizing its development [2]. - The domestic synthetic biology technology sector was in its early stages in 2017, with limited recognition of its application value [2]. Company Profile - Shenzhen Ruidelin Biotechnology Co., Ltd. focuses on synthetic biology technology and has developed over 200 patents related to biosynthetic active ingredients, serving more than 2,000 enterprises [1][3]. - The company aims to address industry pain points by utilizing biosynthetic technology to reduce costs and increase production capacity for peptides [2][3]. Technological Innovation - Ruidelin has established a multidisciplinary green biotechnology manufacturing platform that integrates various engineering disciplines, enhancing research and development efficiency [4]. - The company has incorporated artificial intelligence into enzyme engineering, creating over 50 AI models to optimize enzyme performance, which significantly improves research efficiency [5]. Production Capacity - Ruidelin has invested nearly 200 million yuan to build a green active ingredient smart factory, which includes two hundred-ton production lines and has successfully scaled up production of various products [7]. - The company is constructing a thousand-ton production base in Shaoguan, Guangdong, expected to produce over 1,000 tons of green active ingredients annually, generating more than 2 billion yuan in annual output value [7]. Financial Performance - Since 2022, Ruidelin has experienced continuous revenue growth, with projected revenue exceeding 100 million yuan in 2024 [8].